Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases.

Clin Kidney J · 2023 · PMC10616487 · PMID 37915915

Europe PMC DOI

hedged sentence

0.1060

closest p · 2.1× alpha

0.1060

boldest claim

The sentences

showed a trendP = .106not close (p > 0.1)

In the SRR cohort, sotrovimab showed a trend toward lower outcome risk than molnupiravir [HR 0.39 (95% CI 0.13–1.21); P = .106].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.